



<b>Chapter 3</b>			
<b>Principles of Adaptive Immunity</b>		<b>71</b>	
3-1	Innate and adaptive immunity differ in their strategies for pathogen recognition	71	
3-2	Immunoglobulins and T-cell receptors are the highly variable recognition molecules of adaptive immunity	72	
3-3	The diversity of immunoglobulins and T-cell receptors is generated by gene rearrangement	73	
3-4	Clonal selection of B and T lymphocytes is the guiding principle of the adaptive immune response	75	
3-5	Adaptive immune responses are initiated in secondary lymphoid tissues by antigen-bearing dendritic cells and T cells	75	
3-6	T-cell receptors recognize degraded fragments of pathogen proteins	76	
3-7	T-cell receptors recognize peptide antigens bound to human cell-surface molecules	78	
3-8	Two classes of MHC molecule present peptide antigens to two types of T cell	78	
3-9	MHC class I molecules present antigens of intracellular origin to CD8 T cells	80	
3-10	MHC class II molecules present antigens of extracellular origin to CD4 T cells	81	
3-11	Effector CD4 T cells help B cells become antibody-producing plasma cells	81	
3-12	Extracellular pathogens and their toxins are eliminated by antibodies	83	
3-13	Antibody quality improves during the course of an adaptive immune response	85	
3-14	Immunological memory is a consequence of clonal selection	86	
3-15	Clonal selection makes T cells and B cells tolerant of self and responsive to pathogens	87	
3-16	Unwanted effects of adaptive immunity cause autoimmune disease, transplant rejection and allergy	88	
	<b>Summary to Chapter 3</b>	<b>90</b>	
	<b>Questions</b>	<b>91</b>	
<b>Chapter 4</b>			
<b>Antibody Structure and the Generation of B-Cell Diversity</b>		<b>95</b>	
	<b>The structural basis of antibody diversity</b>	<b>96</b>	
4-1	Antibodies are composed of polypeptides with variable and constant regions	96	
4-2	Immunoglobulin chains are folded into compact and stable protein domains	97	
4-3	An antigen-binding site is formed from the hypervariable regions of a heavy-chain V domain and a light-chain V domain	99	
4-4	Antigen-binding sites vary in shape and physical properties	100	
4-5	Monoclonal antibodies are produced from a clone of antibody-producing cells	102	
4-6	Monoclonal antibodies are used as treatments for a variety of diseases	104	
	<b>Summary</b>	<b>105</b>	
	<b>Generation of immunoglobulin diversity in B cells before encounter with antigen</b>	<b>105</b>	
4-7	The DNA sequence encoding a V region is assembled from two or three gene segments	106	
4-8	Random recombination of gene segments produces diversity in the antigen-binding sites of immunoglobulins	106	
4-9	Recombination enzymes produce additional diversity in the antigen-binding site	108	
4-10	Developing and naive B cells use alternative mRNA splicing to make both IgM and IgD	110	
4-11	Each B cell produces immunoglobulin of a single antigen specificity	111	
4-12	Immunoglobulin is first made in a membrane-bound form that is present on the B-cell surface	111	
	<b>Summary</b>	<b>112</b>	
	<b>Diversification of antibodies after B cells encounter antigen</b>	<b>113</b>	
4-13	Secreted antibodies are produced by an alternative pattern of heavy-chain RNA processing	113	
4-14	Rearranged V-region sequences are further diversified by somatic hypermutation	114	
4-15	Isotype switching produces immunoglobulins with different C regions but identical antigen specificities	115	
4-16	Antibodies with different C regions have different effector functions	117	
	<b>Summary</b>	<b>119</b>	
	<b>Summary to Chapter 4</b>	<b>119</b>	
	<b>Questions</b>	<b>121</b>	
<b>Chapter 5</b>			
<b>Antigen Recognition by T Lymphocytes</b>		<b>125</b>	
	<b>T-cell receptor diversity</b>	<b>126</b>	
5-1	The T-cell receptor resembles a membrane-associated Fab fragment of immunoglobulin	126	
5-2	T-cell receptor diversity is generated by gene rearrangement	127	
5-3	The <i>RAG</i> genes were key elements in the origin of adaptive immunity	129	
5-4	Expression of the T-cell receptor on the cell surface requires association with additional proteins	129	
5-5	A distinct population of T cells expresses a second class of T-cell receptor with $\gamma$ and $\delta$ chains	130	
	<b>Summary</b>	<b>131</b>	
	<b>Antigen processing and presentation</b>	<b>132</b>	
5-6	The two classes of MHC molecule present antigen to CD8 and CD4 T cells, respectively	133	
5-7	The two classes of MHC molecule have similar three-dimensional structures	134	
5-8	MHC molecules bind a variety of peptides	135	
5-9	MHC class I and class II molecules bind peptides in different intracellular compartments	137	
5-10	Peptides generated in the cytosol are transported into the endoplasmic reticulum, where they bind MHC class I molecules	137	

5-11	MHC class I molecules bind antigenic peptide as part of a peptide-loading complex	138			
5-12	Peptides presented by MHC class II molecules are generated in acidified intracellular vesicles	140			
5-13	MHC class II molecules are prevented from binding peptides in the endoplasmic reticulum by the invariant chain	140			
5-14	The T-cell receptor specifically recognizes both peptide and MHC molecule	142			
5-15	The two classes of MHC molecule are expressed differentially on cells	143			
5-16	Cross-presentation allows extracellular antigens to be presented by MHC class I	144			
	Summary	145			
	<b>The major histocompatibility complex</b>	<b>145</b>			
5-17	The diversity of MHC molecules in the human population is due to multigene families and genetic polymorphism	146			
5-18	The HLA class I and class II genes occupy different regions of the HLA complex	147			
5-19	Other proteins involved in antigen processing and presentation are encoded in the HLA class II region	148			
5-20	MHC polymorphism affects the binding and presentation of peptide antigens to T cells	149			
5-21	MHC diversity results from selection by infectious disease	151			
5-22	MHC polymorphism triggers T-cell reactions that can reject transplanted organs	153			
	Summary	154			
	<b>Summary to Chapter 5</b>	<b>154</b>			
	<b>Questions</b>	<b>155</b>			
<b>Chapter 6</b>					
<b>The Development of B Lymphocytes</b>			<b>159</b>		
<b>The development of B cells in the bone marrow</b>			<b>160</b>		
6-1	B-cell development in the bone marrow proceeds through several stages	160			
6-2	B-cell development is stimulated by bone marrow stromal cells	161			
6-3	Pro-B cell rearrangement of the heavy-chain locus is an inefficient process	162			
6-4	The pre-B-cell receptor monitors the quality of immunoglobulin heavy chains	163			
6-5	The pre-B-cell receptor causes allelic exclusion at the immunoglobulin heavy-chain locus	164			
6-6	Rearrangement of the light-chain loci by pre-B cells is relatively efficient	165			
6-7	B cells have to pass two main checkpoints in their development in the bone marrow	167			
6-8	A program of protein expression underlies the stages of B-cell development	168			
6-9	Many B-cell tumors carry chromosomal translocations that join immunoglobulin genes to genes that regulate cell growth	171			
6-10	B cells expressing the glycoprotein CD5 express a distinctive repertoire of receptors	171			
	Summary	173			
	<b>Selection and further development of the B-cell repertoire</b>	<b>174</b>			
6-11	The population of immature B cells is purged of cells bearing self-reactive B-cell receptors	174			
6-12	The antigen receptors of autoreactive immature B cells can be modified by receptor editing	175			
6-13	Immature B cells specific for monovalent self antigens are made nonresponsive to antigen	176			
6-14	Maturation and survival of B cells requires access to lymphoid follicles	177			
6-15	Encounter with antigen leads to the differentiation of activated B cells into plasma cells and memory B cells	179			
6-16	Different types of B-cell tumor reflect B cells at different stages of development	180			
	Summary	182			
	<b>Summary to Chapter 6</b>	<b>182</b>			
	<b>Questions</b>	<b>184</b>			
<b>Chapter 7</b>					
<b>The Development of T Lymphocytes</b>			<b>187</b>		
<b>The development of T cells in the thymus</b>			<b>187</b>		
7-1	T cells develop in the thymus	188			
7-2	Thymocytes commit to the T-cell lineage before rearranging their T-cell receptor genes	190			
7-3	The two lineages of T cells arise from a common thymocyte progenitor	191			
7-4	Gene rearrangement in double-negative thymocytes leads to assembly of either a $\gamma\delta$ receptor or a pre-T-cell receptor	193			
7-5	Thymocytes can make four attempts to rearrange a $\beta$ -chain gene	194			
7-6	Rearrangement of the $\alpha$ -chain gene occurs only in pre-T cells	195			
7-7	Stages in T-cell development are marked by changes in gene expression	196			
	Summary	197			
<b>Positive and negative selection of the T-cell repertoire</b>			<b>198</b>		
7-8	T cells that recognize self-MHC molecules are positively selected in the thymus	199			
7-9	Continuing $\alpha$ -chain gene rearrangement increases the chance for positive selection	200			
7-10	Positive selection determines expression of either the CD4 or the CD8 co-receptor	200			
7-11	T cells specific for self antigens are removed in the thymus by negative selection	202			
7-12	Tissue-specific proteins are expressed in the thymus and participate in negative selection	202			
7-13	Regulatory CD4 T cells comprise a distinct lineage of CD4 T cells	203			
7-14	T cells undergo further differentiation in secondary lymphoid tissues after encounter with antigen	203			
7-15	Most T-cell tumors represent early or late stages of T-cell development	204			
	Summary	205			
	<b>Summary to Chapter 7</b>	<b>205</b>			
	<b>Questions</b>	<b>207</b>			

<b>Chapter 8</b>			
<b>T Cell-Mediated Immunity</b>		<b>211</b>	
	<b>Activation of naive T cells on encounter with antigen</b>	<b>212</b>	
8-1	Dendritic cells carry antigens from sites of infection to secondary lymphoid tissues	212	
8-2	Dendritic cells are adept and versatile at processing antigens from pathogens	213	
8-3	Naive T cells first encounter antigen presented by dendritic cells in secondary lymphoid tissues	215	
8-4	Homing of naive T cells to secondary lymphoid tissues is determined by chemokines and cell-adhesion molecules	216	
8-5	Activation of naive T cells requires a co-stimulatory signal delivered by a professional antigen-presenting cell	219	
8-6	Secondary lymphoid tissues contain three kinds of professional antigen-presenting cell	220	
8-7	When T cells are activated by antigen, signals from T-cell receptors and co-receptors alter the pattern of gene transcription	222	
8-8	Proliferation and differentiation of activated T cells are driven by the cytokine interleukin-2	224	
8-9	Antigen recognition by a naive T cell in the absence of co-stimulation leads to the T cell becoming nonresponsive	226	
8-10	On activation, CD4 T cells acquire distinctive helper functions	227	
8-11	Naive CD8 T cells are activated to become cytotoxic effector cells in several different ways	229	
	Summary	230	
	<b>The properties and functions of effector T cells</b>	<b>231</b>	
8-12	Effector T-cell responses to infection do not depend on co-stimulatory signals	231	
8-13	Effector T-cell functions are carried out by cytokines and cytotoxins	232	
8-14	Cytotoxic CD8 T cells are selective and serial killers of target cells at sites of infection	234	
8-15	Cytotoxic T cells kill their target cells by inducing apoptosis	236	
8-16	T <sub>H</sub> 1 CD4 cells induce macrophages to become activated	237	
8-17	T <sub>H</sub> 1 cells coordinate the host response to pathogens that live in macrophages	239	
8-18	CD4 T <sub>H</sub> 2 cells activate only those B cells that recognize the same antigen as they do	241	
8-19	Regulatory CD4 T cells limit the activities of effector CD4 and CD8 T cells	242	
	Summary	243	
	<b>Summary to Chapter 8</b>	<b>245</b>	
	<b>Questions</b>	<b>245</b>	
<b>Chapter 9</b>			
<b>Immunity Mediated by B Cells and Antibodies</b>		<b>249</b>	
	<b>Antibody production by B lymphocytes</b>	<b>250</b>	
9-1	B-cell activation requires cross-linking of surface immunoglobulin	250	
9-2	B-cell activation requires signals from the B-cell co-receptor	250	
9-3	The antibody response to certain antigens does not require T-cell help	251	
9-4	Activation of naive B cells by most antigens requires help from CD4 T cells	254	
9-5	The primary focus of clonal expansion in the medullary cords produces plasma cells secreting IgM	256	
9-6	Follicular dendritic cells provide long-lasting depositories of B-cell antigens	256	
9-7	Activated B cells undergo somatic hypermutation and isotype switching in the specialized microenvironment of the B-cell zone	257	
9-8	Selection of centrocytes by antigen in the germinal center drives affinity maturation of the B-cell response	259	
9-9	The cytokines made by helper T cells determine how B cells switch their immunoglobulin isotype	261	
9-10	Cytokines made by helper T cells determine the differentiation of antigen-activated B cells into plasma cells or memory cells	262	
	Summary	262	
	<b>Antibody effector functions</b>	<b>263</b>	
9-11	IgM, IgG, and monomeric IgA protect the internal tissues of the body	264	
9-12	Dimeric IgA protects the mucosal surfaces of the body	266	
9-13	IgE provides a mechanism for the rapid ejection of pathogens from the body	267	
9-14	Mothers provide protective antibodies to their young, both before and after birth	268	
9-15	High-affinity neutralizing antibodies prevent viruses and bacteria from infecting cells	268	
9-16	High-affinity IgG and IgA antibodies are used to neutralize microbial toxins and animal venoms	270	
9-17	Binding of IgM to antigen on a pathogen's surface activates complement by the classical pathway	272	
9-18	Two forms of C4 tend to be fixed at different sites on pathogen surfaces	273	
9-19	Complement activation by IgG requires the participation of two or more IgG molecules	274	
9-20	Erythrocytes facilitate the removal of immune complexes from the circulation	275	
9-21	The four subclasses of IgG have different and complementary functions	275	
9-22	Fc receptors enable hematopoietic cells to bind and be activated by IgG bound to pathogens	278	
9-23	A variety of low-affinity Fc receptors are specific for IgG	280	
9-24	IgE binds to high-affinity Fc receptors on mast cells, basophils, and activated eosinophils	282	
9-25	The Fc receptor for monomeric IgA belongs to a different family from the Fc receptors for IgG and IgE	284	
	Summary	285	
	<b>Summary to Chapter 9</b>	<b>285</b>	
	<b>Questions</b>	<b>286</b>	

**Chapter 10**

**The Body's Defenses Against Infection 289**

**Preventing infection at mucosal surfaces 290**

10-1 The communication functions of mucosal surfaces render them vulnerable to infection 290

10-2 The gastrointestinal tract is invested with distinctive secondary lymphoid tissues 291

10-3 M cells and dendritic cells facilitate transport of microbes from the gut lumen to gut-associated lymphoid tissues 293

10-4 Effector lymphocytes populate healthy mucosal tissue in the absence of infection 294

10-5 B cells and T cells commit to mucosal lymphoid tissues after they encounter their specific antigen 296

10-6 Effector lymphocytes activated in any one mucosal tissue recirculate through all mucosal tissues 298

10-7 Dimeric IgA binds pathogens at various sites in mucosal tissues 298

10-8 Two subclasses of IgA have complementary properties for controlling microbial populations 299

10-9 Humans with selective deficiency of IgA do not succumb to infection 300

10-10 Intestinal epithelial cells contribute to innate defense of the gut 301

10-11 Intestinal helminth infections provoke strong T<sub>H</sub>2-mediated immune responses 301

Summary 302

**Immunological memory and the secondary immune response 303**

10-12 The antibodies formed during a primary immune response prevent reinfection for several months after disease 304

10-13 Immunological memory is sustained by clones of long-lived memory T cells and B cells 305

10-14 Vaccination against a pathogen can generate immunological memory that persists for life 306

10-15 Pathogen-specific memory B cells are more abundant and make better antibodies than do naive B cells 307

10-16 Activation of a secondary response involves cell–cell interactions like those activating the primary response 308

10-17 Only memory B cells, and not naive B cells, participate in the secondary immune response 308

10-18 Immune-complex mediated inhibition of naive B cells is used to prevent hemolytic anemia of the newborn 309

10-19 In the response to influenza virus, immunological memory is gradually eroded 310

10-20 Several cell-surface markers distinguish memory T cells from naive T cells 311

10-21 Two types of memory T cell function in different tissues 313

10-22 Maintenance of immunological memory is not dependent on antigen 313

Summary 314

**Bridging innate and adaptive immunity 315**

10-23  $\gamma\delta$  T cells contribute to the innate immune response 315

10-24 Individual NK cells express many different combinations of receptors belonging to one of two receptor families 317

10-25 NK cells use receptors for MHC class I molecules to identify infected cells 318

10-26 NK cells have inhibitory receptors with different specificities for MHC class I molecules 319

10-27 Inhibitory receptors for self MHC class I make NK cells tolerant to self and responsive to loss of MHC class I 321

10-28 T cells recognizing lipid antigens protect against mycobacterial infection 322

10-29 NK T cells are cells of innate immunity that express  $\alpha\beta$  T-cell receptors 323

Summary 323

**Summary to Chapter 10 324**

**Questions 326**

**Chapter 11**

**Failures of the Body's Defenses 329**

**Evasion and subversion of the immune system by pathogens 329**

11-1 Genetic variation within some species of pathogens prevents effective long-term immunity 330

11-2 Mutation and recombination allow influenza virus to escape from immunity 330

11-3 Trypanosomes use gene rearrangement to change their surface antigens 332

11-4 Herpesviruses persist in human hosts by hiding from the immune response 333

11-5 Certain pathogens sabotage or subvert immune defense mechanisms 334

11-6 Bacterial superantigens stimulate a massive but ineffective T-cell response 336

11-7 Immune responses can contribute to disease 337

Summary 337

**Inherited immunodeficiency diseases 338**

11-8 Rare primary immunodeficiency diseases reveal how the human immune system works 338

11-9 Inherited immunodeficiency diseases are caused by dominant, recessive, or X-linked gene defects 339

11-10 Recessive and dominant mutations in the interferon- $\gamma$  receptor cause diseases of differing severity 340

11-11 Antibody deficiency leads to an inability to clear extracellular bacteria 341

11-12 Diminished production of antibodies also results from inherited defects in T-cell help 343

11-13 Defects in complement components impair antibody responses and cause the accumulation of immune complexes 343

11-14 Defects in phagocytes result in enhanced susceptibility to bacterial infection 345

11-15 Defects in T-cell function result in severe combined immune deficiencies 346

11-16	Some inherited immunodeficiencies lead to specific disease susceptibilities	348	12-13	Urticaria, angioedema, and eczema are allergic reactions in the skin	381
11-17	Transplantation of hematopoietic stem cells is used to correct genetic defects of the immune system	349	12-14	Food allergies cause systemic effects as well as gut reactions	382
	Summary	351	12-15	People with parasite infections and high levels of IgE rarely develop allergic disease	383
	<b>Acquired immune deficiency syndrome</b>	<b>351</b>	12-16	Allergic reactions are prevented and treated by three complementary approaches	384
11-18	HIV is a retrovirus that causes slowly progressing disease	351		Summary	385
11-19	HIV infects CD4 T cells, macrophages, and dendritic cells	352		<b>Type II, III, and IV hypersensitivity reactions</b>	<b>386</b>
11-20	Most people who become infected with HIV progress in time to develop AIDS	353	12-17	Type II hypersensitivity reactions are caused by antibodies specific for altered components of human cells	386
11-21	Genetic deficiency of the CCR5 co-receptor for HIV confers resistance to infection	356	12-18	To avoid type II hypersensitivity reactions in blood transfusion, donors and recipients are matched for ABO antigens	387
11-22	HLA and KIR polymorphisms influence the progression to AIDS	356	12-19	Type III hypersensitivity reactions are caused by immune complexes formed from IgG and soluble antigens	389
11-23	HIV escapes the immune response and develops resistance to antiviral drugs by rapid mutation	357	12-20	Systemic disease caused by immune complexes can follow the administration of large quantities of soluble antigens	390
11-24	Clinical latency is a period of active infection and renewal of CD4 T cells	358	12-21	Inhaled antigens can cause type III hypersensitivity reactions	392
11-25	HIV infection leads to immunodeficiency and death from opportunistic infections	359	12-22	Type IV hypersensitivity reactions are mediated by antigen-specific effector T cells	392
	Summary	360	12-23	Celiac disease is caused by hypersensitivity to common food proteins	395
	<b>Summary to Chapter 11</b>	<b>361</b>	12-24	Severe hypersensitivity reactions to certain drugs are strongly correlated with HLA class I allotypes	397
	<b>Questions</b>	<b>361</b>		Summary	398
	<b>Chapter 12</b>			<b>Summary to Chapter 12</b>	<b>398</b>
	<b>Over-reactions of the Immune System</b>	<b>365</b>		<b>Questions</b>	<b>399</b>
12-1	Four types of hypersensitivity reaction are caused by different effector mechanisms of adaptive immunity	365		<b>Chapter 13</b>	
	<b>Type I hypersensitivity reactions</b>	<b>367</b>		<b>Disruption of Healthy Tissue by the Immune Response</b>	<b>403</b>
12-2	IgE binding to FcεR1 provides mast cells, basophils, and activated eosinophils with antigen receptors	367		<b>Autoimmune diseases</b>	<b>403</b>
12-3	Mast cells defend and maintain the tissues where they live	368	13-1	In healthy individuals the immune system is tolerant of self antigens	404
12-4	Tissue mast cells orchestrate IgE-mediated allergic reactions through the release of inflammatory mediators	370	13-2	Autoimmune diseases are caused by the loss of tolerance to self antigens	404
12-5	Eosinophils are specialized granulocytes that release toxic mediators in IgE-mediated responses	371	13-3	The effector mechanisms of autoimmunity resemble those causing hypersensitivity reactions	405
12-6	Basophils are rare granulocytes that initiate T <sub>H</sub> 2 responses and the production of IgE	373	13-4	Endocrine glands contain specialized cells that are targets for organ-specific autoimmunity	407
12-7	Very few antigens that enter the human body are allergens that stimulate an IgE response	374	13-5	Autoimmune diseases of the thyroid can cause either underproduction or overproduction of thyroid hormones	408
12-8	Predisposition to allergic disease has a genetic basis	376	13-6	Ectopic lymphoid tissue can form at sites inflamed by autoimmune disease	409
12-9	IgE-mediated allergic reactions consist of an immediate response followed by a late-phase response	377	13-7	The cause of an autoimmune disease can be revealed by the transfer of the disease by immune effectors	410
12-10	The effects of IgE-mediated allergic reactions vary with the site of mast-cell activation	378	13-8	Type 1 diabetes is caused by the selective destruction of insulin-producing cells in the pancreas	411
12-11	Systemic anaphylaxis is caused by allergens in the blood	379			
12-12	Rhinitis and asthma are caused by inhaled allergens	380			

13-9	Autoantibodies against common components of human cells can cause systemic autoimmune disease	412	14-5	The need for a vaccine and the demands placed on it change with the prevalence of the disease	444
13-10	Most rheumatological diseases are caused by autoimmunity	413	14-6	Vaccines have yet to be found for many chronic pathogens	446
13-11	Rheumatoid arthritis can be treated with monoclonal antibodies that target either TNF- $\alpha$ or B cells	413	14-7	Genome sequences of human pathogens open up new avenues of vaccine design	447
13-12	Multiple sclerosis and myasthenia gravis are autoimmune diseases of the nervous system	414	14-8	A useful vaccine against HIV has yet to be found	449
	Summary	416	14-9	An effective and acceptable rotavirus vaccine has been developed	450
	<b>Genetic and environmental factors predispose to autoimmune disease</b>	<b>417</b>	14-10	Vaccine development faces greater public scrutiny than drug development	450
13-13	All autoimmune diseases involve breaking T-cell tolerance	417		<b>Summary to Chapter 14</b>	<b>451</b>
13-14	Incomplete deletion of self-reactive T cells in the thymus causes autoimmune disease	417		<b>Questions</b>	<b>452</b>
13-15	Insufficient control of T-cell co-stimulation favors autoimmunity	418		<b>Chapter 15</b>	
13-16	Regulatory T cells protect cells and tissues from autoimmunity	419		<b>Transplantation of Tissues and Organs</b>	<b>455</b>
13-17	HLA is the dominant genetic factor affecting susceptibility to autoimmune disease	420	15-1	Transplant rejection and graft-versus-host reaction are immune responses caused by genetic differences between transplant donors and recipients	455
13-18	Different combinations of HLA class II allotypes confer susceptibility and resistance to diabetes	422	15-2	Blood transfusion is the most widespread kind of transplantation in clinical medicine	456
13-19	Autoimmunity is initiated by disease-associated HLA allotypes presenting antigens to autoimmune T cells	424		<b>Transplantation of solid organs</b>	<b>458</b>
13-20	Noninfectious environmental factors influence the course of autoimmune diseases	425	15-3	Antibodies against ABO or HLA antigens cause hyperacute rejection of transplanted organs	458
13-21	Genetic and environmental effects combine to cause one form of rheumatoid arthritis	426	15-4	Anti-HLA antibodies can arise from pregnancy, blood transfusion, or previous transplants	459
13-22	Infections are environmental factors that can trigger autoimmune disease	427	15-5	Organ transplantation involves procedures that inflame the donated organ and the transplant recipient	460
13-23	Autoimmune T cells can be activated in a pathogen-specific or nonspecific manner by infection	428	15-6	Acute rejection is caused by effector T cells responding to HLA differences between donor and recipient	460
13-24	In the course of autoimmune disease the specificity of the autoimmune response broadens	430	15-7	HLA differences between transplant donor and recipient activate numerous alloreactive T cells	462
13-25	Senescence of the T-cell population can contribute to autoimmunity	432	15-8	Negative selection in the thymus limits the number of expressed MHC isoforms	462
13-26	Does the current increase in hypersensitivity and autoimmune disease have a common cause?	432	15-9	Chronic rejection of organ transplants is due to the indirect pathway of allorecognition	462
	Summary	433	15-10	Matching donor and recipient for HLA class I and class II allotypes improves the outcome of organ transplantation	466
	<b>Summary to Chapter 13</b>	<b>433</b>	15-11	Allogeneic transplantation is made possible by the use of three types of immunosuppressive drug	466
	<b>Questions</b>	<b>434</b>	15-12	Corticosteroids change patterns of gene expression	467
	<b>Chapter 14</b>		15-13	Cytotoxic drugs kill proliferating cells	469
	<b>Vaccination to Prevent Infectious Disease</b>	<b>437</b>	15-14	Cyclosporin A, tacrolimus, and rapamycin selectively inhibit T-cell activation	470
14-1	Viral vaccines are made from whole viruses or viral components	437	15-15	Antibodies specific for T cells are used to prevent and control acute rejection	472
14-2	Bacterial vaccines are made from whole bacteria, their secreted toxins, or capsular polysaccharides	439	15-16	Patients needing a transplant outnumber the available organs	473
14-3	Adjuvants nonspecifically enhance the immune response	441			
14-4	Vaccination can inadvertently cause disease	443			

15-17	The need for HLA matching and immunosuppressive therapy varies with the organ transplanted	474		
	Summary	475		
	<b>Transplantation of hematopoietic stem cells</b>	<b>476</b>		
15-18	Bone marrow transplantation is a treatment for genetic diseases of blood cells	476		
15-19	Allogeneic bone marrow transplantation is the preferred treatment for many cancers	477		
15-20	The alloreaactions in bone marrow transplantation attack the patient, not the transplant	477		
15-21	Matching donor and recipient for HLA class I and II is particularly important in bone marrow transplantation	479		
15-22	HLA-identical bone marrow transplants cause GVHD through recognition of minor histocompatibility antigens	480		
15-23	Some GVHD helps engraftment and prevents relapse of malignant disease	481		
15-24	NK cells also mediate GVL effects	482		
15-25	Hematopoietic cell transplantation can induce tolerance to solid organ transplants	483		
	Summary	484		
	<b>Summary to Chapter 15</b>	<b>484</b>		
	<b>Questions</b>	<b>485</b>		
			<b>Chapter 16</b>	
			<b>Cancer and Its Interactions with the Immune System</b>	<b>489</b>
16-1	Cancer results from mutations that cause uncontrolled cell growth	490		
16-2	A cancer arises from a single cell that has accumulated multiple mutations	491		
16-3	Exposure to chemicals, radiation, and viruses can facilitate the progression to cancer	492		
16-4	Certain common features distinguish cancer cells from normal cells	494		
16-5	Immune responses to cancer have similarities with those to virus-infected cells	494		
16-6	Differences in MHC class I allow tumor cells to be attacked and eliminated by cytotoxic T cells	495		
16-7	Mutations in cellular genes acquired during oncogenesis provide tumor-specific antigens	496		
16-8	Cancer/testis antigens are a prominent type of tumor-associated antigen	498		
16-9	Successful tumors evade and manipulate the immune response	498		
16-10	By preventing infection, vaccination protects against cancers caused by viruses	500		
16-11	Vaccination with tumor antigens can cause cancer to regress	500		
16-12	Increasing co-stimulation can boost the T-cell response to tumor cells	501		
16-13	Heat-shock proteins can provide natural adjuvants of tumor immunity	501		
16-14	Monoclonal antibodies against cell-surface tumor antigens can be used for diagnosis and immunotherapy	502		
	<b>Summary to Chapter 16</b>	<b>504</b>		
	<b>Questions</b>	<b>505</b>		